JP Patent

JP7428356B2 — 高いバイオアベイラビリティを有するソラフェニブの医薬組成物、ソラフェニブ経口固形製剤、及びその使用

Assigned to Beijing Creatron Institute of Pharmaceutical Research Co Ltd · Expires 2024-02-06 · 2y expired

What this patent protects

Patent listed against tenapanor-hydrochloride.

Drugs covered by this patent

tenapanor-hydrochloride (TENAPANOR HYDROCHLORIDE)

Patent Metadata

Patent number: JP7428356B2
Jurisdiction: JP
Classification: —
Expires: 2024-02-06
Drug substance claim: No
Drug product claim: No
Assignee: Beijing Creatron Institute of Pharmaceutical Research Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.